VRDN
Viridian Therapeutics Inc
NASDAQ · Biotechnology
$29.25
+0.08 (+0.27%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 441.6K | 945.1K | 406.82M | 430.67M | 340.92M |
| Net Income | -399,135,280 | -768,717,637 | -22,289,343 | -19,976,292 | -17,345,815 |
| EPS | — | — | — | — | — |
| Profit Margin | -89,387.1% | -84,917.7% | -5.5% | -4.6% | -5.1% |
| Rev Growth | -53.3% | -53.3% | +16.2% | -2.2% | +21.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 43.59M | 43.59M | 669.82M | 633.24M | 687.59M |
| Total Equity | 1.42B | 1.42B | 2.33B | 2.30B | 2.45B |
| D/E Ratio | 0.03 | 0.03 | 0.29 | 0.27 | 0.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -441,402,567 | -897,351,676 | -26,538,842 | -30,128,222 | -24,250,802 |
| Free Cash Flow | — | — | -14,865,013 | -23,390,816 | -14,209,915 |